Dr. Nanzha Abi, MPH

Before joining the Emory Epidemiology program, Nanzha completed her M.D. and M.S. degree in internal medicine and led several clinical research projects on chronic kidney disease and dialysis patients. As a researcher interested in kidney disease, Nanzha is particularly drawn to using genetic techniques to identify novel biomarkers and potential therapeutic targets, with the ultimate goal of improving patient outcomes. In her free time, I enjoy working out, taking care of animals and learning languages.

Matheus Fernandes Gyorfy, MPH

Matheus (Matt) is a third-year Epidemiology PhD student at Emory University. He completed his undergraduate studies at Colorado State University, where he double majored in Biological Sciences and Languages, Literatures, and Cultures. Matt acquired his Master of Public Health degree in 2023 from Emory University.

In his doctoral research, Matt has focused his efforts on the intersection of multi-omics and infectious diseases, where he is investigating the genetic mechanisms behind resistance to Mycobacterium tuberculosis (Mtb)infection in ancestrally diverse populations. In parallel, Matt is researching the role of epigenetics in the complex, bidirectional relationship between hyperglycemia and Mtb infection. Furthermore, Matt serves as the lead analyst on a project dedicated to understanding epigenetic patterns and accelerated biological aging among individuals with latent Mtb infection.

Dr. Jeffery Osei, MD, MPH

Dr. Jeffery Osei is a second-year PhD (epidemiology) student, also pursuing a certificate in Genetic and Molecular Epidemiology (GME). Before coming to Emory for my MPH, he earned his M.D. and worked as a general practitioner in Ghana. Currently, Jeffery currently works as a clinical research coordinator and a research assistant at Emory University Hospital and the Centers for Disease Control and Prevention’s Office of Genomics and Precision Public Health, respectively. Jeffery is interested in clinical and translational research on cardiovascular disease and precision public health. In particular, the use of genetic epidemiologic methods and mobile health technologies, to identify novel biomarkers, understand risk factors and biological mechanisms underlying CVD, and develop therapeutic and preventive strategies.